

### **Supplementary material 1: Qualifications of experts selected in the expert group**

**(Patient)** Ms. Leontine Sidje is the president of the RIP+ association, the main patient association of patients living with HIV. She plays a key role in promoting patient centered health policies in Côte d'Ivoire. For example, she was part of the representatives for patients' associations at the ICASA (International Conference of AIDS and STDs in Africa).

**(Decision maker)** Dr Jean-Marie Masumbuko is a member of the Country Coordination Mechanism of the Global Fund in Côte d'Ivoire. The Global Fund is, with the PEPFAR, the main funding source for HIV programs in Côte d'Ivoire. This position gives him a clear view of the current programs and experimentations in HIV care funded in the country and the feasibility of health system interventions.

**(Director of a HIV clinic)** Dr Eugene Messou is the director of one of the largest HIV clinic in West Africa (CEPREF, Abidjan). This position allowed him to have a relevant expertise in the feasibility of organization level interventions.

**(Public Health specialist)** Pr Didier Ekouevi is a public health specialist and one the main investigators of the IeDEA project for West Africa. He provided insights into the feasibility of propositions in a wider context (in different health and care systems with different resource availability).

**(Physician)** Dr Jean Baptiste N'takpé is a physician with training in clinical research. His opinions were useful to assess the feasibility of propositions at the consultation level.

**(Social worker)** Ms. Suzanne Kouadio is a social worker involved in HIV care for more than 20 years. She has large experience in the operation of an HIV clinic and her point of view was important because she usually works in closer collaboration with patients than physicians.

**Supplementary material 2: Demographic and clinical characteristics of respondents and non-respondents to the qualitative survey**

<b>Patient characteristics</b>	<b>Respondents (n=326)</b>	<b>Non-respondents (n=150)</b>	<b>P value</b>
<b>Age (years) – Mean (SD)</b>	45 (9.4)	44 (9.0)	0.33
<b>Female sex – No. (%)</b>	230 (70.5)	114	0.26
<b>Relationship status – No. (%)</b>			
Single	110 (33.7)	52 (34.7)	0.59
Married	169 (51.8)	72 (48.0)	
Widow, divorced, separated	46 (14.1)	26 (17.3)	
<b>Educational level – No. (%)</b>			
Non-formal	61 (18.7)	35 (23.3)	0.57
Primary	88 (27.0)	43 (28.7)	
Secondary	127 (38.9)	52 (34.7)	
Higher than secondary	50 (15.3)	20 (13.3)	
<b>Unemployed – No. (%)</b>	41 (12.6)	17 (11.3)	0.81
<b>Monthly income (USD) – No. (%)</b>			
<99	157 (48.1)	73 (48.7)	0.10
99–166	85 (26.1)	31 (20.7)	
167–498	63 (19.3)	40 (26.7)	
>498	18 (5.5)	3 (2)	
<b>Last CD4 count – Mean (SD)</b>	565 (260)	594 (301)	0.31
<b>Viral load &lt;100 cp/mL – No. (%)</b>	43 (13.2)	22 (14.7)	0.77
<b>ART duration (years) – Mean (SD)</b>	7.4 (3.6)	6.6 (3.5)	0.02
<b>Total no. of pills per day – Mean (SD)</b>	5.6 (3.9)	5.6 (3.7)	0.95
<b>Treatment Burden Questionnaire (TBQ) score – Mean (SD)</b>	31.3 (20.5)	28.2 (19.4)	0.11